Pfizer (PFE) Stock Looks Overvalued After Updated COVID Vaccine Approval

Pfizer stock has delivered a 25.6% return over the past year, yet the overall valuation checks point to a mixed picture rather than a clear bargain or clear premium at current levels.

• The 25.6% one-year gain signals a solid rebound in sentiment that may already reflect some of the good news around the business.
• Approval of Pfizer and BioNTech's updated XFG adapted COVID 19 vaccine can support expectations for ongoing vaccine revenue, while pressure on wider pharmaceutical pricing and competition in key therapies may limit how much investors are willing to pay for those cash flows.
• With a value score of 3 and market multiples that screen as overvalued, Pfizer looks neither obviously cheap nor clearly expensive on the broader checks.

The issue now is whether Pfizer's recent share price recovery already captures the main drivers of its future cash flows, or if there is still room for valuation to adjust further.

Spot potential peers to Pfizer by scanning hand picked solid balance sheet and fundamentals stocks screener (53 results), which may pair resilient balance sheets with more attractive valuation profiles.

Does Pfizer Look Pricey on Earnings?

The P/E ratio is a good fit for Pfizer because earnings remain a key anchor for how investors think about large pharmaceutical stocks. Pfizer currently trades on a P/E of 37.8x, which is more than double the Pharmaceuticals industry average of 16.3x and still below the peer group average of 56.4x.

The fair P/E ratio implied by the broader checks is 28.4x, so the current 37.8x level suggests the stock screens overvalued on this earnings-based lens even after that peer comparison. Despite the recent FDA approval of the updated XFG adapted COVID 19 vaccine supporting sentiment around ongoing product revenue, the market is already asking investors to pay a premium multiple for Pfizer relative to what the model flags as a more balanced level.

On the P/E multiple, Pfizer stock looks overvalued compared with both its tailored fair ratio and the wider industry benchmark.

See what the numbers say about this price — find out in our valuation breakdown.

The Pfizer Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Pfizer valuation puzzle leaves off by spelling out which paths for Pfizer's growth, margins and earnings would need to play out for the stock to be worth materially more or materially less than the current price. Each narrative links its number to a clear view on how growth, profitability and risks could evolve, which you can revisit on the Community page as fresh information comes through.

The community views on Pfizer are pulled in two very different directions, which shows how much hinges on how you see the pipeline and the patent risks.

Bull case: roughly fairly valued

"Robust expansion of Pfizer's late-stage pipeline, especially in oncology and rare diseases, with multiple high-potential launches and label expansions (e.g., Elrexfio in multiple myeloma, SV in non-small cell lung cancer, advanced ADC portfolio, and pipeline vaccines), stands to drive sustained long-term revenue and earnings growth by addressing rising global demand for innovative therapies as the population ages…"

Read the full Bull Case to see why Pfizer could be undervalued

Bear case: roughly fairly valued

"O 'patent cliff' maior se concentra entre 2026-2030, com até US$ 17-18 bilhões em receitas anuais em risco de drogas como Eliquis, Vyndaqel, Prevnar, Ibrance e Xtandi enfrentando genéricos…"

Read the full Bear Case to see why Pfizer could be overvalued

Do you think there's more to the story for Pfizer? Head over to our Community to see what others are saying!

The Bottom Line

Pfizer stock currently screens as overvalued on its P/E based checks, so the easy valuation case no longer rests on buying it at a clear discount. For you as an investor, the real question is whether Pfizer can deliver enough earnings growth and product execution to make that richer multiple feel comfortable over time. The crux of the bull versus bear debate is how effectively the company can offset patent risks and competitive pressure with its pipeline and newer launches, and whether the market keeps paying up for that story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com